Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

← catalyst calendar

NCT07217886

Sponsored by Shionogi (industry) · 4507.T — their whole pipeline →. With Biomedical Advanced Research and Development Authority.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24actual
Sites
4
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-10-16actualWhen the study began enrolling
Primary completion2026-02-13actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-02-13actualThe whole study's end, after follow-up
First posted2025-10-20actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-07-13actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Renal Impairment

Intervention

  • Drug: S-892216-PO

Primary outcomes

what the primary-completion date above is the date OF
Maximum Plasma Concentration (Cmax) of S-892216
measured Day 1 (predose up to 504 hours postdose) and Day 29 (predose up to 72 hours postdose) for Group B participants only
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration After Dosing (AUC0-last) of S-892216
measured Day 1 (predose up to 504 hours postdose) and Day 29 (predose up to 72 hours postdose) for Group B participants only
Group B Only: Cumulative Amount of the Drug Recovered in Dialysate (AHD) of S-892216
measured Day 1 (up to 6 hours postdose)
Group B Only: Area Under the Dialysate Concentration in the Arterial Sides of Port-time Curve During Hemodialysis (AUChd) of S-892216
measured Day 1 (up to 6 hours postdose)

Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed